ASTRAZENECA AB
🇪🇸Spain
Appeals Court Rejects AstraZeneca's Challenge to Medicare Drug Price Negotiation Program
• The 3rd U.S. Circuit Court of Appeals dismissed AstraZeneca's lawsuit against Medicare's drug price negotiation program, ruling the company failed to demonstrate specific injury or due process violations.
• The Medicare negotiation program, established under the Inflation Reduction Act, affects AstraZeneca's diabetes drug Farxiga, with negotiated prices set to take effect next year for 66 million Medicare beneficiaries.
• While AstraZeneca's challenge was rejected, a separate lawsuit by PhRMA and other pharmaceutical companies was revived by the 5th Circuit Court in September, creating conflicting judicial responses to industry challenges.
Advancements in Targeted Therapies Improve Survival in Breast Cancer
• Recent trials highlight the benefits of CDK4/6 inhibitors like abemaciclib and ribociclib in high-risk, HR+/HER2- early breast cancer, improving invasive disease-free survival.
• Checkpoint inhibitors such as pembrolizumab and nivolumab show promise in treating high-risk, HR+/HER2- breast cancer, particularly in patients with high PDL1 expression and low estrogen receptor expression.
• Trastuzumab deruxtecan has demonstrated improved progression-free survival in HER2-low, HR+/HER2- metastatic breast cancer, marking a significant advancement in treatment options.
• The RxPONDER trial indicates that adjuvant chemotherapy may not benefit all premenopausal patients, with AMH levels predicting which patients will benefit from chemotherapy.
© Copyright 2025. All Rights Reserved by MedPath